Stockreport

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting [Yahoo! Finance]

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF XTANDI can be given alone or in combination with androgen deprivation therapy Approval is based on results from the positive Phase 3 EMBARK study which showed XTANDI [Read more]